Collaborative Approaches to Lead Generation

[1]  Yanli Wang,et al.  PubChem: Integrated Platform of Small Molecules and Biological Activities , 2008 .

[2]  Robert H Bates,et al.  Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection , 2013, PloS one.

[3]  A. Parrill,et al.  S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. , 2005, Chemistry & biology.

[4]  Shaoyou Chu,et al.  Open Innovation for Phenotypic Drug Discovery: The PD2 Assay Panel , 2011, Journal of biomolecular screening.

[5]  David M. Wilson,et al.  A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery , 2013, PloS one.

[6]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[7]  Barry J. Hardy,et al.  Collaborative virtual organisation and infrastructure for drug discovery. , 2013, Drug discovery today.

[8]  Christian Scheurer,et al.  Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria , 2011, Proceedings of the National Academy of Sciences.

[9]  O. Gassmann,et al.  The Future of Open Innovation , 2010 .

[10]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[11]  Thierry Kogej,et al.  Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case. , 2013, Drug discovery today.

[12]  I. Khanna,et al.  Drug discovery in pharmaceutical industry: productivity challenges and trends. , 2012, Drug discovery today.

[13]  B. Nare,et al.  SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis , 2011, PLoS neglected tropical diseases.

[14]  Bruce Russell,et al.  Spiroindolones, a Potent Compound Class for the Treatment of Malaria , 2010, Science.

[15]  Stephen Gabriel,et al.  Metal impurities cause false positives in high-throughput screening campaigns. , 2013, ACS medicinal chemistry letters.

[16]  Jeremy N. Burrows,et al.  The Open Access Malaria Box: A Drug Discovery Catalyst for Neglected Diseases , 2013, PloS one.

[17]  James R. Brown,et al.  Thousands of chemical starting points for antimalarial lead identification , 2010, Nature.

[18]  Paul Morgan,et al.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.

[19]  B. Munos,et al.  Can Open‐Source Drug R&D Repower Pharmaceutical Innovation? , 2010, Clinical pharmacology and therapeutics.

[20]  Clifton E. Barry,et al.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.

[21]  Andrew L Hopkins,et al.  The Joint European Compound Library: boosting precompetitive research. , 2015, Drug discovery today.

[22]  J. Pandit,et al.  Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia. , 2012, ACS medicinal chemistry letters.

[23]  Michael Williams,et al.  Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences? , 2011, Journal of Pharmacology and Experimental Therapeutics.

[24]  N. Quashie,et al.  Functional characterization of both MAP kinases of the human malaria parasite Plasmodium falciparum by reverse genetics , 2007, Molecular microbiology.